Cargando…

Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by transcriptome analysis

TP53 is the most frequently mutated gene in human cancer. While no TP53-targeting drugs have been approved in the USA or Europe so far, preclinical and clinical studies are underway to investigate targeting of specific or all TP53 mutations, for example, by restoration of the functionality of mutate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Romanovsky, Eva, Kluck, Klaus, Ourailidis, Iordanis, Menzel, Michael, Beck, Susanne, Ball, Markus, Kazdal, Daniel, Christopoulos, Petros, Schirmacher, Peter, Stiewe, Thorsten, Stenzinger, Albrecht, Budczies, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10104808/ https://www.ncbi.nlm.nih.gov/pubmed/37059713 http://dx.doi.org/10.1038/s41420-023-01413-1

Ejemplares similares

Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types
por: Budczies, Jan, et al.
Publicado: (2022)

Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD)
por: Menzel, Michael, et al.
Publicado: (2023)

Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer
por: Stögbauer, Fabian, et al.
Publicado: (2023)

Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK(+) Lung Cancer Patients with Poor Survival
por: Christopoulos, Petros, et al.
Publicado: (2019)

Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)
por: Rempel, E., et al.
Publicado: (2022)

p53 partial loss-of-function mutations sensitize to chemotherapy
por: Klimovich, Boris, et al.
Publicado: (2021)

A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy—EGFR mutated non-small cell lung cancer IV patients treated with osimertinib
por: Roeper, Julia, et al.
Publicado: (2022)

Defining molecular risk in ALK(+) NSCLC
por: Christopoulos, Petros, et al.
Publicado: (2019)

Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types
por: Budczies, Jan, et al.
Publicado: (2017)

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report
por: Ball, Markus, et al.
Publicado: (2022)

Ioncopy: an R Shiny app to call copy number alterations in targeted NGS data
por: Budczies, Jan, et al.
Publicado: (2018)

A nomogram prediction model for the TP53mut subtype in endometrial cancer based on preoperative noninvasive parameters
por: Wang, Wei, et al.
Publicado: (2023)

Die Verordnung (EU) 2017/746 (IVDR) in der Praxis: Umsetzung von Anhang I in der Pathologie
por: Kahles, Andy, et al.
Publicado: (2023)

The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma
por: Kirchner, M., et al.
Publicado: (2021)

Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer
por: Elsayed, Mei, et al.
Publicado: (2021)

Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing
por: Neumann, Olaf, et al.
Publicado: (2022)

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report
por: Blasi, Miriam, et al.
Publicado: (2021)

Keratin homogeneity in the tail feathers of Pavo cristatus and Pavo cristatus mut. alba
por: Pabisch, S., et al.
Publicado: (2010)

Cyanobacteria of Greece: an annotated checklist
por: Gkelis, Spyros, et al.
Publicado: (2016)

p53’s Extended Reach: The Mutant p53 Secretome
por: Pavlakis, Evangelos, et al.
Publicado: (2020)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report
por: Wiedemann, Christiane, et al.
Publicado: (2022)

MutS/MutL crystal structure reveals that the MutS sliding clamp loads MutL onto DNA
por: Groothuizen, Flora S, et al.
Publicado: (2015)

Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma
por: Fisch, David, et al.
Publicado: (2021)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

The Presence of the DNA Repair Genes mutM, mutY, mutL, and mutS is Related to Proteome Size in Bacterial Genomes
por: Garcia-Gonzalez, Aurian, et al.
Publicado: (2012)

Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer
por: Magios, Nikolaus, et al.
Publicado: (2021)

A Novel Variant in the TP53 Gene Causing Li–Fraumeni Syndrome
por: Papadimitriou, Dimitrios T., et al.
Publicado: (2023)

RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples
por: Kirchner, Martina, et al.
Publicado: (2019)

Struktur und Inhalt der EU-IVDR: Bestandsaufnahme und Implikationen für die Pathologie
por: Kahles, Andy, et al.
Publicado: (2022)

Structure and content of the EU-IVDR: Current status and implications for pathology
por: Kahles, Andy, et al.
Publicado: (2023)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Rahmé, Ramy, et al.
Publicado: (2023)

The TP53 fertility network
por: Paskulin, Diego d’Avila, et al.
Publicado: (2012)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_0ruu5suc7kfu6r3oeeffv76i1d